|
About the Statistics and Pharmacometrics (SxP) category
|
|
0
|
1197
|
February 19, 2016
|
|
Summary Statistics for Blinded Clinical Trial Results
|
|
4
|
256
|
September 27, 2019
|
|
Statistics and Pharmacometrics Blog
|
|
7
|
1237
|
October 12, 2017
|
|
DIA ADSWG Adaptive Dose Individualization (announcement & invitation)
|
|
0
|
757
|
August 25, 2017
|
|
Symposium on Dose Selection for Cancer Treatment Drugs
|
|
0
|
770
|
April 24, 2017
|
|
What are the sticking points between statistics and pharmacometrics?
|
|
9
|
2038
|
April 19, 2017
|
|
Variability, Uncertainty, and Error
|
|
4
|
2937
|
March 29, 2017
|
|
When is a result worth noting? A quick thought on pharmacometrics and multiplicity
|
|
5
|
1556
|
March 15, 2017
|
|
Optimal PK sampling shedule
|
|
5
|
2688
|
March 13, 2017
|
|
Survey to Help in Planning
|
|
0
|
827
|
March 10, 2017
|
|
2016 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
|
|
0
|
935
|
October 19, 2016
|
|
Announcing SxP (Statistics and Pharmacometrics Interest Group)
|
|
0
|
1077
|
May 27, 2016
|
|
My Career as a Pharmacometrician and Commentary on the Overlap Between Statistics and Pharmacometrics in Drug Development
|
|
0
|
1430
|
February 20, 2016
|
|
ACoP 